Navigation Links
What does the public really know about HPV?

Human papillomaviruses (HPV) are the most common sexually transmitted infections in the United States, and certain "high risk" types have been shown to cause cervical cancer. Despite recent advances in the detection and prevention of HPV, the link between the virus and cervical cancer is not well known to the public. In June 2006, the Food and Drug Administration (FDA) approved the first vaccine to prevent infection of two high risk types of HPV, and two types that cause genital warts. The Advisory Committee on Immunization Practices (ACIP) recommended it for females 9 to 26 years of age.

Two studies presented today at the American Association for Cancer Research's Frontiers in Cancer Prevention Research meeting in Boston assess the public's understanding of HPV and whether discussion of the vaccine by the media and public has influenced the decision to vaccinate among women at risk.

What Do U.S. Women Know About Human Papillomavirus (HPV) and Cervical Cancer?

Many women with HPV show no symptoms of the virus, and infections often clear without need for treatment. Because of this, many women do not have the opportunity to speak with their physicians about HPV and therefore may not learn that some HPV infections are persistent and can develop into cervical cancer.

The National Cancer Institute (NCI) created the Health Information National Trends Survey (HINTS) to monitor health communications about cancer. In 2005, one high-priority research aim was to assess, for the first time, the awareness and knowledge of HPV in a nationally representative sample of women.

To identify factors associated with U.S. women's awareness of HPV and its link to cervical cancer, researchers from NCI analyzed cross-sectional data collected from more than 3,000

women ages 18 to 75 who responded to HINTS. Researchers found that:

  • Only 40 percent had ever heard about HPV;
  • Among them, less than ha
    '"/>


Source:American Association for Cancer Research


Page: 1 2 3 4

Related biology news :

1. New push for public health, AIDS spending at African Union summit
2. Wiley announces publication of Databasing the Brain
3. BioMed Central welcomes the new National Institutes of Health public access policy
4. Not-for-profit publishers call NIH public access rule a missed opportunity
5. CoPub Mapper: mining MEDLINE based on search term co-publication
6. DOE JGI launches IMG public online microbial genome data clearinghouse
7. Understanding biases in epidemic models important when making public health predictions
8. Does manganese inhaled from the shower represent a public health threat?
9. Center releases new public survey on stem cells
10. HIV-infected adults in Botswana respond positively to ARV therapy public treatment program
11. Scientists fetch useful information from dog genome publications
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: What does the public really know about HPV

(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... 27, 2015   Marvin Test Solutions ... innovative test solutions for military, aerospace, and ... its TS-323 GENASYS Test Platform ... GENASYS is a high-performance PXI-based system designed ... that require performance functional testing. GENASYS features ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... at the University of Cincinnati (UC) have found a ... to therapies to prevent the development of the nation,s ... findings will be presented for the first time at ... Nov. 17. The study, led by WenFeng Cai, ...
... a drug already approved for treating multiple sclerosis show ... bioterrorist attack with botulinum neurotoxin which is 10,000 ... known to man. The potential drugs also could be ... well as Alzheimer,s disease, multiple sclerosis, and myasthenia gravis, ...
... presented at the 2010 FIP Pharmaceutical Sciences World Congress ... Annual Meeting and Exposition will highlight a targeted inhalable ... of needle avoidance and expected lower cost than the ... world. HPV is the number one ...
Cached Biology News:Researchers discover potential genetic target for heart disease 2New needle-free HPV vaccine increases effectiveness, availability in developing world 2
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
(Date:2/26/2015)... 26, 2015 S&P Capital IQ (MHFI) announced ... coverage on MabVax Therapeutics Holdings Inc . ... stage biotechnology company focused on the development of vaccine ... the treatment of cancer. MabVax has discovered a pipeline ... immune responses generated by patients who have been immunized ...
(Date:2/26/2015)... 26, 2015   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today reported ... goals, other key objectives, and financial guidance.  Synageva,s ... at 4:30 p.m. EST to review the financial ... participate in today,s call by telephone, please dial ...
(Date:2/26/2015)... Angeles, CA (PRWEB) February 26, 2015 ... an online demonstration to support life extension technologies and ... 8pm UTC, Universal Coordinated Time, on March 21st 2015, ... the world. , Eric Schulke, Founder of MILE, ... must act with urgency. The Movement for Indefinite Life ...
Breaking Biology Technology:Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3
... Conn., March 29, 2011 USChina Channel LLC announced today: ... Commonwealth Biotechnologies Inc. ("CBI") filed Form 8-k of SEC, to ... The vote process is going very well. We ... stock made the vote. Followings are the interim vote results ...
... March 29, 2011 AMDeC, LLC ... Program to include products offered by Sigma® Life ... of Sigma-Aldrich® (Nasdaq: SIAL).  AMDeC is a consortium ... New York region that is focused on increasing ...
... (OTC Bulletin Board: SNGX ) (Soligenix or ... financial results for the year ended December 31, 2010. ... December 31, 2010 were $1,947,628 as compared to $2,816,037 ... or 31%.  During 2009, Soligenix received a $1 million ...
Cached Biology Technology:Commonwealth Biotechnologies 2011 Annual Shareholder Vote & Meeting Update Information 2Commonwealth Biotechnologies 2011 Annual Shareholder Vote & Meeting Update Information 3Sigma® Life Science Joins AMDeC's Vendor Partnership Program, Further Enhancing Value to Academic Medical Research Centers 2Sigma® Life Science Joins AMDeC's Vendor Partnership Program, Further Enhancing Value to Academic Medical Research Centers 3Sigma® Life Science Joins AMDeC's Vendor Partnership Program, Further Enhancing Value to Academic Medical Research Centers 4Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments 2Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments 3Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments 4Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments 5
Mouse monoclonal [HL-37] to HLA DQ1 + HLA DQ3 ( Abpromise for all tested applications)....
SHEEP ANTI BOVINE BETA-LACTOGLOBULIN A...
... Convenient platform for tube handling and reagent dispensing ... V-bottom tubes - 96 x 0.3ml ... - Thermo-Fast® 96 Non-Skirted Plate ... 48 x 0.5ml Thermo-Tubes Multiple workstations can be securely ...
6B9...
Biology Products: